AlphaCore Capital
BMRN icon

AlphaCore Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

AlphaCore Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$382K Buy
6,367
+2,706
+74% +$170K 0.01% 966
2026
Q2 		$209K Sell
3,661
-512
-12% -$28K ﹤0.01% 1091
2026
Q1 		$236K Buy
+4,173
New +$243K 0.01% 779

Other funds holding BMRN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
ARGA Investment Management
ARGA Investment Management Stamford, Connecticut $3.94B AUM 28.9% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

AlphaCore Capital's BMRN Position: Q3 2026 in Review

AlphaCore Capital increased its BioMarin Pharmaceuticals (BMRN) stake by 74% in Q3 2026, buying an estimated $170K and bringing the position to 6,367 shares worth $382K. The position accounts for 0.01% of the portfolio, ranked #966.

AlphaCore Capital first reported a position in BMRN in Q1 2026 and has held it in 3 quarters since. 249 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • AlphaCore Capital held 6,367 shares of BioMarin Pharmaceuticals worth $382K as of Q3 2026.
  • AlphaCore Capital bought 2,706 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $170K.
  • BioMarin Pharmaceuticals made up 0.01% of AlphaCore Capital's portfolio in Q3 2026, its #966 holding.
  • AlphaCore Capital first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 249 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.